The critically ill patient frequently develops a complex disease spectrum that includes sepsis syndrome and/or septic shock. A major cause of delayed deaths in the critically ill patient is multiple organ dysfunction syndrome (MODS). Current knowledge suggests that MODS is related to dysregulation of innate immunity which can involve a hyperinflammatory shock like state resulting in disseminated tissue injury as well as a prolong immune suppression that can predispose to opportunistic infections. The presence of myocardial dysfunction in patients with sepsis/septic shock/MODS is well known. Recent evidence indicates that the innate immune response plays a central role in the pathophysiology of cardiac dysfunction in sepsis/septic shock. However, the mechanisms by which innate immunity mediates cardiac dysfunction are only now coming to the light. Furthermore, the physiologic mechanisms that attempt to limit the inflammatory response, promote survival of cardiac myocytes, and maintain cardiovascular homeostasis in sepsis/septic shock remain unclear. Toll-like receptor (TLR)-mediated signaling plays a critical role in the induction of innate and inflammatory responses. Our preliminary data indicate that TLR2 and TLR4 have strikingly different and opposing, i.e. differential, effects on cardiac function during sepsis/septic shock. Our data also suggest that modulation of TLR2/TLR4-dependent signaling pathways may be an effective approach for preventing/managing cardiac dysfunction in sepsis/septic shock. The experiments outlined in this application will test the hypothesis that differential modulation of TLR2 and TLR4 signaling pathways determine the fate of cardiac function in response to sepsis/septic shock insult. To test this hypothesis, we will pursue three specific aims. 1. We will elucidate the mechanisms by which TLR4 deficiency attenuates cardiac dysfunction in sepsis/septic shock 2. We will define the mechanisms by which modulation of TLR2 improves cardiac function in sepsis/septic shock. 3. We will investigate whether differential regulation of TLR2/4 and PI3K/Akt signaling pathways has an additive effect on cardioprotection during sepsis/septic shock. These studies will provide a mechanistic understanding of the signaling pathways that are critical for myocardial function and/or dysfunction in sepsis. It may also be possible to apply this knowledge in a practical fashion to identify new and novel therapeutic approaches to prevent or manage cardiac dysfunction in sepsis/septic shock.
The critically ill patient frequently develops a complex disease spectrum that may include acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), sepsis syndrome and/or septic shock and multiple organ dysfunction syndrome (MODS). In the United States ~750,000 patients/year develop sepsis syndrome. Of these patients, the overall mortality rate is 28.6% (~215,000 deaths/year). Those patients that survive the initial event, which may include trauma, may ultimately succumb to widespread organ dysfunction that can be either acute, due to hyper-inflammatory responses, or more prolonged due immune dysfunction and infection. Indeed, sepsis is a frequent cause of MODS. It is well known that cardiovascular dysfunction is also associated with MODS morbidity and mortality. Attempts at developing effective therapies for sepsis/septic shock and MODS has proven to be exceedingly difficult. This is due, in part, to our incomplete understanding of the cellular and molecular mechanisms that mediate cardiac dysfunction in sepsis. Thus, it is clear that a better understanding of the molecular mechanisms leading to cardiac dysfunction during sepsis/septic shock is essential in developing adjunctive therapies that could decrease both morbidity and mortality. These studies will provide a mechanistic understanding of the cellular signaling pathways that are critical for myocardial function and/or dysfunction in sepsis. It may also be possible to apply this knowledge in a practical fashion to identify new and novel therapeutic approaches to prevent or manage cardiac dysfunction in sepsis/septic shock.
|Hadebe, Sabelo; Kirstein, Frank; Fierens, Kaat et al. (2016) Î²-Glucan exacerbates allergic airway responses to house dust mite allergen. Respir Res 17:35|
|Elder, Matthew J; Webster, Steven J; Williams, David L et al. (2016) TSLP production by dendritic cells is modulated by IL-1Î² and components of the endoplasmic reticulum stress response. Eur J Immunol 46:455-63|
|Monroe, Lizzie L; Armstrong, Michael G; Zhang, Xia et al. (2016) Zymosan-Induced Peritonitis: Effects on Cardiac Function, Temperature Regulation, Translocation of Bacteria, and Role of Dectin-1. Shock 46:723-730|
|Ma, He; Wang, Xiaohui; Ha, Tuanzhu et al. (2016) MicroRNA-125b Prevents Cardiac Dysfunction in Polymicrobial Sepsis by Targeting TRAF6-Mediated Nuclear Factor ÎºB Activation and p53-Mediated Apoptotic Signaling. J Infect Dis 214:1773-1783|
|Hadebe, Sabelo; Kirstein, Frank; Fierens, Kaat et al. (2015) Microbial Ligand Costimulation Drives Neutrophilic Steroid-Refractory Asthma. PLoS One 10:e0134219|
|Lu, Chen; Wang, Xiaohui; Ha, Tuanzhu et al. (2015) Attenuation of cardiac dysfunction and remodeling of myocardial infarction by microRNA-130a are mediated by suppression of PTEN and activation of PI3K dependent signaling. J Mol Cell Cardiol 89:87-97|
|Zhang, Xia; Ha, Tuanzhu; Lu, Chen et al. (2015) Poly (I:C) therapy decreases cerebral ischaemia/reperfusion injury via TLR3-mediated prevention of Fas/FADD interaction. J Cell Mol Med 19:555-65|
|Noss, Ilka; Ozment, Tammy R; Graves, Bridget M et al. (2015) Cellular and molecular mechanisms of fungal Î²-(1â†’6)-glucan in macrophages. Innate Immun 21:759-69|
|Gao, Ming; Wang, Xiaohui; Zhang, Xia et al. (2015) Attenuation of Cardiac Dysfunction in Polymicrobial Sepsis by MicroRNA-146a Is Mediated via Targeting of IRAK1 and TRAF6 Expression. J Immunol 195:672-82|
|Smeekens, Sanne P; Gresnigt, Mark S; Becker, Katharina L et al. (2015) An anti-inflammatory property of Candida albicans Î²-glucan: Induction of high levels of interleukin-1 receptor antagonist via a Dectin-1/CR3 independent mechanism. Cytokine 71:215-22|
Showing the most recent 10 out of 36 publications